IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans

Biological Psychiatry

Volumn 47, Issue 5, 2000, Pages 450-462

  D'Souza, Deepak Cyril ^a,b   Gil, Roberto ^a,b   Cassello, Karyn ^a,b   Morrissey, Kristen ^a,b   Abi Saab, Danielle ^a,b   White, Jonathan ^a,b   Sturwold, Robert ^a   Bennett, Alexandre ^a,b   Karper, Laurence P ^a,b   Zuzarte, Edward ^a,b   Charney, Dennis S ^b   Krystal, John H ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amino acids; Cerebrospinal fluid; D cycloserine; Glycine; NMDA receptors; Strychnine insensitive

Indexed keywords

CYCLOSERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; PLACEBO;

ARTICLE; BIOAVAILABILITY; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; NEUROTRANSMISSION; NORMAL HUMAN; PRIORITY JOURNAL; STARTLE REFLEX;

ACOUSTIC STIMULATION; ADMINISTRATION, ORAL; ADULT; AMINO ACIDS; ANTIMETABOLITES; BIOLOGICAL AVAILABILITY; CYCLOSERINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLYCINE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE; STARTLE REACTION;

EID: 17144455141     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00133-X     Document Type: Article

References (63)

1. Al-Amin H.A., Schwarzkopf S.B. Effects of the PCP analog dizocilpine on sensory gating Potential relevance to clinical subtypes of schizophrenia . Biol Psychiatry. 40:1996;744-754.
2. Bacopoulos N.G., Redmond D.E., Roth R.H. Serotonin and dopamine metabolites in brain regions and cerebrospinal fluid of a primate species Effects of ketamine and fluphenazine . J Neurochem. 32:1979;1215-1218.
3. Bakshi V.P., Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology. 122:1995;198-201.
4. Bristow L.J., Landon L., Saywell K.L., Tricklebank M.D. The glycine/NMDA receptor antagonist, L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat. Psychopharmacology. 118:1995;230-232.
5. th Annual Meeting of the American College of Neuropsychopharmacology. Waikoloa, Hawaii; pp 303.
6. th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico; pp 200.
7. th International Congress on Schizophrenia Research. Colorado Springs, Colorado; Vol. 24, pp 211.
8. Borkowski J.G., Benton A.L., Spreen O. Word fluency and brain damage. Neuropsychologia. 5:1967;135-140.
9. Borowsky B., Mezey E., Hoffman B.J. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron. 10:1992;851-863.
10. Brandt J. Hopkins verbal memory test. Clin Neuropsychol. 5:1991;125-142.
11. Buchanan B.W., Heinrichs D.W. Neurological Evaluation Scale (NES) A structured instrument for the assessment of neurological signs in schizophrenia . Psychiatry Res. 27:1989;335-350.
12. Conzelman G.M. The physiological disposition of D-cycloserine in the human subject. Am Rev Tubercul Pulmn Dis. 74:1956;739-746.
13. Crema A., Berte F. Uber die Verteilung und Stoffwechsel des cycloserins bei der ratte, naunyn-schmeid. Arch Exp Pathol Pharmacol. 239:1960;475.
14. D'Souza D.C., Charney D.S., Krystal J.H. Glycine site agonists of the NMDA receptor A review . CNS Drug Rev. 1:(2):1995;150-186.
15. D'Souza DC, Gil R, Belger A, et al (1997): Glycine ketamine interactions in healthy humans. Annual Meeting of the American College of Neuropsychopharmacology. Hawaii, December 1997.
16. Dunlop D.S., Neidle A. The origin and turnover of D-serine in brain. Biochem Biophys Res Comm. 235:1997;26-30.
17. Emmett M.R., Mick S.J., Cler J.A., Rao T.S., Iyengar S., Wood P.L. Actions of D-cycloserine at the NMDA associated glycine receptor site in vivo. Neuropharmacology. 30:1991;1167-1171.
18. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state A practical method of grading the cognitive state of patients for the clinician . J Psychiat Res. 12:1975;189-198.
19. Forsythe I.D., Westbrook G.L., Mayer M.L. Modulation of excitatory synaptic transmission by glycine and zinc in cultured mouse hippocampal neurons. Eur J Neurosci. 8:1988;3733.
20. Furuya Y., Ogura H. Competitive NMDA and strychnine-insensitive glycine-site antagonists disrupt prepulse inhibition. Pharmacol Biochem Behav. 57:1997;909-913.
21. Globus M.Y.T., Busto R., Martinez E., Valdes I., Dietrich W.D., Ginsberg M.D. Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine and gamma-aminobutyric acid in vulnerable and non-vulnerable brain regions in the rat. J Neurochem. 57:1991;470-478.
22. Goff D.C., Tsai G., Levitt J., et al. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics. Arch Gen Psychiatry. 56:1999;21-27.
23. Grillon C., Ameli R., Charney D.S., Krystal J.H., Braff D. Schizophrenics disruption of pre-pulse inhibition of the startle reflex is independent of pre-pulse intensity. Biol Psychiatry. 32:1992;939-943.
24. Henderson G., Johnson J., Ascher P. Competitive antagonists and partial agonists at the glycine modulatory site of the mouse NMDA receptor. J Physiol. 430:1990;189-212.
25. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 56:1999;29-36.
26. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Brit J Psychiatry. 169:1996;610-617.
27. Heresco-Levy U., Silipo G., Javitt D.C. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull. 32:1996;731-740.
28. Holdiness M.R. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 10:1985;532-534.
29. Hood W.F., Compton R.P., Monahan J.B. D-cycloserine: a ligand for the NMDA coupled glycine receptor has partial agonist characteristics. Neurosci Lett. 98:1989;91-95.
30. Iwama H., Takahashi K., Kure S., et al. Depletion of cerebral D-serine in non-ketotic hyperglycinemia Possible involvement of glycine cleavage system in control of endogenous D-serine . Biochem Biophys Res Comm. 231:1997;793-796.
31. Javitt D.C., Frusciante M. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake Implications for schizophrenia and substance abuse . Psychopharmacology. 129:1997;96-98.
32. Javitt D.C., Sershen H., Hashim A., Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology. 17:1997;202-204.
33. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmaye J. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
34. thAnnual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico; pp 201.
35. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse neurons. Nature. 325:1987;529-531.
36. Kemp J.A., Leeson P.D. The glycine site of the NMDA receptor - five years on. TIPS. 14:1993;20-25.
37. Kikuo K., Hitoshi S., Tsutsumo N., Hiroaki S., Shinichi S. Glycine stimulates growth hormone release in man. Acta Endocrinol Scand. 93:1980;283-286.
38. Kleckner N.W., Dingeldine R. Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science. 241:1988;835-837.
39. Kucera H., Francis W.N. Computational Analysis of Present Day American English. 1967;Brown University Press, Providence.
40. Krystal J.H., Webb E., Grillon C., et al. Evidence of acoustic startle hyperreflexia in recently detoxified alcoholics Modulation by yohimbine and m-chlorphenylpiperazine (mCPP) . Psychopharmacology. 131:1997;207-215.
41. Leiderman E., Zylberman I., Zukin S.R., Cooper T.B., Javitt D.C. Preliminary investigation of high dose oral glycine on serum levels and negative symptoms in schizophrenia An open label trial . Biol Psychiatry. 39:1996;213-215.
42. Lerma J., Herranz A.S., Herreras O., Abriara V., Del Rio R.M. In vivo determination of extracellular concentrations of amino acids in the rat hippocampus. A method based on brain microdialysis and computerized analysis. Brain Res. 384:1986;145-155.
43. Mandell GL, Sardt MA (1985): The Pharmacological Basis of Therapeutics. Goodman A, Gilman A, editors. New York: Macmillan, pp 1203.
44. McBain C.J., Kleckner N.W., Wyrick S., Dingledine R. Structural requirements for activation of the glycine coagonist site of the NMDA receptors expressed in Xenopus oocytes. Mol Pharmacol. 36:1989;556-565.
45. 3H]glycine recognition site as a modulatory site of the N-methyl-D-aspartate receptor complex. J Neurochem. 53:1989;370-375.
46. Nair KGS, Epstein IG, Baron H, Mulinos MG (1956): Absorption, distribution and excretion of cycloserine in man. Antibiot Ann 136-140.
47. Naglak M., Salvo R., Madsen K., Dembure P., Elsas L. The treatment of isovaleric acidemia with glycine supplement. Pediatr Res. 24:1988;9-13.
48. Popa M., Florea I. Growth hormone release by glycine injected intravenously in 22 healthy immature children. Biomedicine. 23:1975;131-133.
49. Preston J.E., Segal M.B., Walley G.J., Zlokovic B.V. Neutral amino acid uptake by the isolated perfused sheep choroid plexus. J Physiol. 408:1989;31-43.
50. Richter J.J., Wainer A. Evidence for separate systems for the transport of neutral and basic amino acids across the blood brain barrier. J Neurochem. 18:1971;613-620.
51. Ronne-Engstrom E., Hillerd L., Flink R., Spannare B., Ungerstedt U., Carlson H. Intracerebral microdialysis of extracellular amino acids in the human epileptic focus. J Cereb Blood Flow Metab. 12:1992;873-876.
52. Schirch L.V. Serine hydroxymethyl transferase. Adv Enzymol. 53:1982;83-112.
53. Slosson R.L. Slosson Intelligence Test (SIT) for Children and Adults. 1963;Slosson Educational Publications, East Aurora, NY.
54. Smith K.E., Borden L.A., Hartig P.R., Branchek T., Weinshank R.L. Cloning and expression of a glycine transporter reveal co-localization with NMDA receptors. Neuron. 8:1992;927-935.
55. Spitzer RL, Williams JB, Gibbon M, First MB (1990): Structured Clinical Interview for DSM-III-R. Biometrics Research.
56. Storey P.B., McLean R.L. A current appraisal of cycloserine. Antibiot Med Clin Ther. 4:1957;223-232.
57. Takahashi K., Hayashi F., Nishikawa T. In vivo evidence for the link between L- and D-serine metabolism in rat cerebral cortex. J Neurochem. 69:1997;1286-1290.
58. Thomson A.M. Glycine is a coagonist at the NMDA receptor/channel complex. Prog Neurobiol. 53:1990;53-74.
59. Thureen P.J., Narkewicz M.R., Battaglia F.C., Tjoa S., Fennessey P.V. Pathways of serine and glycine metabolism in primary culture of ovine fetal hepatocytes. Pediatr Res. 38:1995;775-782.
60. Truong D.D., Fahn S. Therapeutic trial with glycine in myoclonus. Movement Disorders. 3:1988;222-232.
61. Watson G., Lanthorn T. Pharmacological characteristics of cyclic analogues of glycine at the NMDA receptor associated glycine site. Neuropharmacology. 29:1990;727-730.
62. Wlaz P., Baran H., Losher W. Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice. Eur J Pharmacol. 257:1994;217-225.
63. Zieske L.R., Davis L. Decarboxylation of glycine by serine hydroxymethyl transferase in the presence of lipoic acid. J Biol Chem. 258:1983;10355-10359.